Ticlopidine-associated pancytopenia: Implications of an acetylsalicylic acid alternative

Canadian Journal of Cardiology

Volumn 13, Issue 10, 1997, Pages 909-913

  Gill, Sabrina ^a   Majumdar, Sumit ^a   Brown, Neil E ^a   Armstrong, Paul W ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

Author keywords

Acetylsalicylic acid; Granulocyte colony stimulating factor; Granulocyte macrophage colony stimulating factor; Neutropenia; Ticlopidine

Indexed keywords

ANTITHROMBOCYTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TICLOPIDINE;

ADULT; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HEMATOPOIESIS; HUMAN; NEUTROPENIA; PANCYTOPENIA; RESPIRATORY DISTRESS;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG RESISTANCE; FATAL OUTCOME; FEMALE; HUMANS; MIDDLE AGED; NEUTROPENIA; PANCYTOPENIA; PLATELET AGGREGATION INHIBITORS; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, ADULT; TICLOPIDINE;

EID: 0030827629     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ito MK, Smith AR, Lee ML. Ticlopidine: A new platelet aggregation inhibitor. Clin Pharm 1992;11:603-17.
2. Gent M, Easton JD, Blakely JA, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-20.
3. Hass WK, Easton DJ, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-7.
4. Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina: a controlled multicentre clinical trial. Circulation 1990;82:17-26.
5. Limet R, David J, Magotteaux P, Larock M, Rigo P. Prevention of aorta-coronary bypass graft occlusion - beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thorac Cardiovasc Surg 1987;94:773-83.
6. Knudson JB, Kjoller E, Skagen K, Gormsen J. The effect of ticlopidine on platelet functions in acute myocardial infarction. Thromb Haemost 1985;53:332-6.
7. Cloarec M, Caillard P, Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Thromb Res 1986;42(Suppl vi):160. (Abst)
8. Schomig A, Neumann F, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary stents. N Engl J Med 1996;334:1084-9.
9. Takishita S, Kawazoe N, Yoshida T, Fukiyama K. Ticlopidine and thrombocytopenia. N Engl J Med 1990;323:1487-8. (Lett)
10. Page Y, Tardy B, Zeni F, et al. Thrombotic thrombocytopenic purpura related to ticlopidine. Lancet 1991;337:774-6.
11. Kovacs MJ, Soong PY, Chin-Yee IH. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Pharmacother 1993;27:1060-1.
12. Capra R, Marciano N, Fieni F, Capucci M, Ferremi P, Orlandini A. Cerebral hemorrhage and thrombotic thrombocytopenic purpura during ticlopidine therapy: case report. Acta Neurol Belg 1992;92:83-7.
13. Elle E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G. Thrombotic thrombocytopenic purpura associated with ticlopidine. Stroke 1992;23:922-3.
14. Khelif A, Assouline D, French M, Chaumentin G, Viala J. Ticlopidine and aplastic anemia. Br J Haematol 1993,83:678-81.
15. Mataix R, Ojeda E, Perez M, Jimenez S. Ticlopidine and severe aplastic anemia. Br J Haematol 1992;80:125-32.
16. Garnier G, Taillan B, Pesce A, Chichmanian R, Dujardin P. Ticlopidine and severe aplastic anemia. Br J Haematol 1993,81:459-60. (Lett)
17. Mallet L, Mallet J. Ticlopidine and fatal aplastic anemia in an elderly woman. Ann Pharmacother 1994;28:1169-71.
18. Troussard X, Mayo P, Mosquet B, Reman O, Leporrier M. Ticlopidine and severe aplastic anemia. Br J Haematol 1993;83:779-80. (Lett)
19. Janzon L, Bergqvist D, Boberg J, et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication: effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990;227:301-8.
20. Carlson JA, Maesner JE. Fatal neutropenia and thrombocytopenia associated with ticlopidine. Ann Pharmacother 1994;28:1236-8.
21. Pillans PI, Koopowitz A. Captopril-associated agranulocyosis -a report of 3 cases. S Afr Med J 1991;79:399-400.
22. Haynes RB, Sandier RS, Larson EB, Pater JL, Yatsu FM. A critical appraisal of ticlopidine, a new antiplatelet agent. Arch Intern Med 1992;152:1376-80.
23. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol 1991;37:239-42.
24. Guerciolini R, Giordana G, Aversa F, Del Favero A. Anemia and agranulocytosis associated with ticlopidine therapy. Acta Haematol 1985;73:232-4.
25. Nand S, Bayer R, Prinz R, Felten W, Godwin JE. Granulocyte-macrophage colony stimulating factor for the treatment of drug induced agranulocytosis. Am J Hematol 1991;37:267-9.
26. Ruiz-Irastorza G, Alonso JJ, Iglesias JJ, Aguirre C. Granulocyte colony-stimulating factor for neucropenia secondary to ticlopidine. Acta Haematol 1994;91:106-7.
27. Quaglino D, Salladini G, Ricciotti M. Possible mechanism of action of ticlopidine on committed granulocyte macrophage precursers. Haematologica 1984;69:257-61.
28. Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York: Oxford University Press, 1991:3-158.
29. Delannoy A. GM-CSF therapy for drug-induced agranulocytosis. J Intern Med 1992;231:269-71.
30. Julia A, Olona M, Bueno J, et al. Drug-induced agranulocytosis: Prognostic factors in a series of 168 episodes. Br J Haematol 1991;79:366-71.
31. Handin R. Platelets and coronary artery disease. N Engl J Med 1996;334:1126-7. (Edit)
32. Bittl J. Advances in coronary angioplasty. N Engl J Med 1996;335:1290-302.
33. CAPRIE Steering Committee. A randomized, blinded trial of clopidrogel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-38.
34. Hsu VD. DUE criteria for use of ticlopidine in adult inpatients and outpatients. Clin Pharm 1993;12:64-6.